|

IBI343 Clinical Trials

4 actively recruiting trials across 1 location

Pipeline

Phase 1: 1Phase 2: 1Phase 3: 1Phase 1/2: 1

Top Sponsors

  • Innovent Biologics (Suzhou) Co. Ltd.2
  • Zhejiang University1
  • Ruijin Hospital1

Indications

  • Cancer4
  • Locally Advanced (Unresectable) or Metastatic Solid Tumors1
  • Advanced Pancreatic Cancers1
  • Pancreatic Cancer1
  • Gastric Cancer1

Other3 trials

A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Phase 3
IBI343 Combined With Chemotherapy in Advanced Pancreatic Cancer
Phase 2
IBI343 Combined With Sintilimab Plus Chemotherapy in Gastric Cancer
Phase 1/2

Austin, Texas1 trial

A First-in-human Study of IBI343 in Subjects With Locally Advanced Unresectable or Metastatic Solid Tumors

NEXT Austin

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.